Form 4: Cytosorbents CEO Exercises Rights, Acquires Shares and Warrants

Cytosorbents CEO Phillip P. Chan exercised subscription rights to acquire shares and warrants, increasing his stake in the company.

Summary

• Phillip P. Chan, CEO of Cytosorbents Corp, exercised subscription rights on January 17, 2025, acquiring 90,832 shares of common stock at $1.00 per share.
• The transaction also included the acquisition of Series A and Series B warrants, each for 90,832 shares.
• The Series A warrants expire 45 days after the closing date of January 10, 2025, and the exercise price will be 90% of the 5-day volume weighted average price of the common stock, with a floor of $1.00 and a ceiling of $2.00.
• The Series B warrants expire 90 days after the closing date of January 10, 2025, and the exercise price will be 90% of the 5-day volume weighted average price of the common stock, with a floor of $2.00 and a ceiling of $4.00.
• Chan's total holdings include 1,243,195 shares of common stock, including vested and unvested restricted stock units (RSUs).

Sentiment

Score: 7

Explanation: The document reflects a positive action by the CEO, demonstrating confidence in the company. However, it also highlights potential future dilution, which is a neutral factor.

Positives

• The CEO's participation in the rights offering demonstrates confidence in the company's future.
• The exercise of subscription rights provides the company with $90,832 in capital.

Risks

• The value of the warrants is dependent on the future performance of the company's stock price.
• The exercise of the warrants could dilute existing shareholders if the warrants are exercised.

Future Outlook

The document does not contain any specific forward-looking statements, but the exercise of warrants could lead to future share dilution if exercised.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It reflects the CEO's participation in a recent rights offering.

Comparison to Industry Standards

• The exercise of subscription rights and the acquisition of warrants are common practices for executives in publicly traded companies.
• The terms of the warrants, including the exercise price and expiration dates, are typical for such instruments.
• The reporting of these transactions via SEC Form 4 is a standard regulatory requirement.

Stakeholder Impact

• Shareholders may experience dilution if the warrants are exercised.
• The company has received $90,832 in capital from the CEO's participation in the rights offering.

Next Steps

• The Series A and Series B warrants will become exercisable based on the stock price and will expire on February 24, 2025 and April 10, 2025 respectively.

Key Dates

Keywords

Cytosorbents, Phillip P. Chan, subscription rights, warrants, common stock, insider trading, SEC Form 4, rights offering